PHIO: RXi Pharmaceuticals Company Aggregate Debts

Phio Pharmaceuticals generates revenue through the licensing of RNA oncology products, creating a sustainable cash flow. Changes in debt load clearly demonstrate a financial strategy where the 0.00 indicator determines the metric's magnitude. Phio Pharmaceuticals is implementing innovative self-delivering skin cancer therapy to increase treatment precision. Development stability is guaranteed by a strong team of scientists, protected from transitioning to corporate behemoths by long-term options.

For Phio Pharmaceuticals (PHIO), which funds the development of RNA interference while incurring operating losses, the cost of servicing borrowed capital is critical. This total liabilities metric aggregates short-term and long-term loans, reflecting the business's degree of dependence on external financing to sustain clinical trials. Analyzing the trend of total liabilities allows for an assessment of default risk and the company's resilience to cash flow gaps.